US Anticoagulation Therapy Market by Product ((Anticoagulants Drugs (NOACs, Warfarin)), PT/INR Devices (In-Office, Home Testing)), Service Type (Testing & Consulting), Type of Clinic (Hospital Associated, Independent & Pharmacy-based) - Forecast to 2022

抗凝固療法の米国市場予測(~2022年)

◆タイトル:US Anticoagulation Therapy Market by Product ((Anticoagulants Drugs (NOACs, Warfarin)), PT/INR Devices (In-Office, Home Testing)), Service Type (Testing & Consulting), Type of Clinic (Hospital Associated, Independent & Pharmacy-based) - Forecast to 2022
◆商品コード:MD-5704
◆調査・発行会社:MarketsandMarkets
◆発行日:2017年11月3日
◆ページ数:88
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アメリカ
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥621,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"抗凝固療法の米国市場予測(~2022年)"について調査・分析し、イントロダクション、市場概観、市場の成長要因、阻害要因、市場の機会と課題、市場の動態、市場規模及び予測、主要企業(ベンダー)分析等の情報をお届けいたします。

“The US anticoagulation therapy market projected to grow at a CAGR of 8.5%.”The US anticoagulation therapy market is projected to reach USD 27.83 billion by 2022 from an estimated USD 18.49 billion in 2017, at a CAGR of 8.5%. The US anticoagulation therapy market is segmented into products (anticoagulation drugs, PT/INR testing devices) and anticoagulation clinics. The growth of the anticoagulation drugs market is primarily driven by the rising incidence of venous thromboembolism, atrial fibrillation, and stroke; long-term administration and high volume of recurring sales of anticoagulation drugs; and increasing demand for novel oral anticoagulants (NOACs). On the other hand, the high cost of NOACs and requirement of significant investments in the development of anticoagulation drugs are the major factors restraining the growth of this market. In addition, the growth of the anticoagulation clinics market is primarily driven by the increasing prevalence of cardiovascular diseases & blood disorders, high level of medication adherence associated with clinics, and rising aging population.
“The NOACs segment is expected to grow at the highest CAGR during the forecast period.”
The anticoagulation therapy market for drugs is categorized into NOACs, warfarin (VKA), and other drugs. The NOACs segment is expected to grow at the highest CAGR during the forecast period. Due to the better safety and efficacy of NOACs, as compared to traditional therapies, the adoption of NOACs is higher as compared to traditional drugs. In addition, key market players such as Portola Pharmaceuticals (received the FDA approval for its NOAC—Betrixaban in July 2017) are focusing on the development of NOACs in order to capitalize on the growth opportunities presented by this shift in market dynamics. Consequently, many other companies are also expected to focus on developing more safe and efficient NOACs in the coming years; this will ensure the continued growth of this segment.
“By type of clinics, the pharmacy-based anticoagulation clinics segment is expected to grow at the highest CAGR during the forecast period.”
On the basis of clinics type, the US anticoagulation therapy market for clinics market is categorized into hospitals associated clinics, independent clinics, and pharmacy-based clinics. The pharmacy-based clinics segment is expected to grow at the highest CAGR during the forecast period. In the US, the number of pharmacy-based anticoagulation clinics has increased significantly in the last few years. This due is to the fact that better results are achieved when therapy is managed by expert pharmacists rather than care provided by family physicians. Moreover, the cost of therapy provided by pharmacy-based anticoagulation clinics is comparatively lesser than independent and hospital associated anticoagulation clinics which is expected to drive the market for pharmacy-based anticoagulation clinics.
Break of primary participants was as mentioned below:
• By Company Type – Tier 1–46%, Tier 2–36% and Tier 3–18%
• By Designation – C-level–22%, Director Level–45%, Others–33%
Market players such as C. H. Boehringer Sohn (Germany), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer (US), Daiichi Sankyo (Japan), and Portola Pharmaceuticals (US) are the major market players in the US anticoagulation therapy market for drugs while Roche (Switzerland), Abbott (US), Siemens (Germany), Alere (US), and CoaguSense (US) are the major market players in the US anticoagulation therapy market for PT/INR home testing devices.
Research Coverage:
The US anticoagulation therapy market in this report is segmented by products and clinics. It provides detailed information regarding major factors influencing the growth market (drivers, restraints, and industry-specific opportunities). The study tracks and analyzes competitive developments (such as new product developments and R&D activities) and profiles the key players in the US anticoagulation therapy market.
Reasons to buy this report:
From an insight perspective, this research report has focused on various levels of analysis—market share of NOACs, company profiles, emerging and high-growth segments of the US anticoagulation therapy market; market drivers, restraints, and opportunities. The report provides the latest reimbursement trends for PT/INR testing, revenue structure, business models of anticoagulation clinics and in-depth impact analysis of NOACs on anticoagulation clinics, allowing buyers to identify the high growth product segment and potential customers and suppliers hence driving revenue growth and profitability.
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on anticoagulation therapy solutions offered by the top players in the US anticoagulation therapy market

• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the US anticoagulation therapy market

• Market Diversification: Exhaustive information about new products, recent developments, and investments in the US anticoagulation therapy market

• Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the US anticoagulation therapy market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 10
1.1 OBJECTIVES OF THE STUDY 10
1.2 MARKET DEFINITION 10
1.3 MARKET SCOPE 11
1.3.1 MARKETS COVERED 11
1.3.2 YEARS CONSIDERED FOR THE STUDY 11
1.4 CURRENCY 12
1.5 STAKEHOLDERS 12
2 RESEARCH METHODOLOGY 13
2.1 RESEARCH APPROACH 13
2.1.1 SECONDARY DATA 14
2.1.2 PRIMARY DATA 15
2.1.2.1 Breakdown of primary interviews 16
2.1.2.2 Key industry insights 16
2.2 MARKET SIZE ESTIMATION 17
2.2.1 MARKET SIZING METHODOLOGY FOR ANTICOAGULATION DRUGS AND PT/INR TESTING DEVICES 18
2.2.2 MARKET SIZING METHODOLOGY FOR ANTICOAGULATION THERAPY FOR CLINICS 20
2.2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 21
2.2.4 MARKET SHARE ESTIMATION 22
2.2.5 ASSUMPTIONS FOR THE STUDY 22
3 MARKET OVERVIEW 23
3.1 MARKET DYNAMICS: ANTICOAGULATION DRUGS 23
3.1.1 DRIVERS 24
3.1.1.1 Rising incidence of venous thromboembolism, atrial fibrillation, and stroke 24
3.1.1.2 Increasing demand for NOACs as alternatives to warfarin 24
3.1.1.3 Growing number of patients requiring lifelong anticoagulation therapy 25
3.1.2 MARKET RESTRAINTS 25
3.1.2.1 High price of NOACs 25
3.1.2.2 High development expenditure, stringent regulations 26
3.1.3 MARKET OPPORTUNITIES 26
3.1.3.1 Increase in outpatient management of anticoagulation therapy 26
3.1.3.2 Development of NOAC reversal agents 27

3.2 MARKET DYNAMICS: ANTICOAGULATION CLINICS 28
3.2.1 KEY MARKET DRIVERS 28
3.2.1.1 Increasing prevalence of CVD and blood disorders 28
3.2.1.2 High level of medication adherence 29
3.2.1.3 Growth in the geriatric population 29
3.2.2 MARKET RESTRAINTS 30
3.2.2.1 Rising adoption of NOACs 30
3.2.2.2 Demand for alternative treatments 31
3.2.2.3 Home PT/INR testing 31
3.2.3 MARKET OPPORTUNITIES 32
3.2.3.1 Development of alternative approaches 32
4 MARKET INSIGHTS 33
4.1 INTRODUCTION 33
4.2 NUMBER OF ANTICOAGULATION CLINICS 33
4.3 BUSINESS MODELS OF ANTICOAGULATION CLINICS 34
4.3.1 REVENUE STRUCTURE 34
4.3.2 INFRASTRUCTURE REQUIREMENTS FOR SUSTAINING IN THE MARKET 35
4.3.2.1 Role of teleconsultation and telemonitoring 35
4.3.2.2 Role of electronic health record in anticoagulation clinics 37
4.4 REIMBURSEMENT SCENARIO (CMS & PRIVATE PAYERS) 37
4.4.1 REIMBURSEMENT RATE (2016–2017) 37
4.4.1.1 Reimbursement for PT/INR testing 37
4.4.1.2 Reimbursement for evaluation and management service associated with anticoagulation therapy 45
4.4.2 REIMBURSEMENT TRENDS FOR ANTICOAGULATION THERAPY 46
4.5 IMPACT OF NEW ORAL ANTICOAGULANTS (NOACS) ON ANTICOAGULATION CLINICS 48
5 US ANTICOAGULATION THERAPY (PRODUCTS) MARKET 51
5.1 US ANTICOAGULATION THERAPY (PRODUCTS) MARKET FOR DRUGS 52
5.1.1 INTRODUCTION 52
5.1.2 NOVEL ORAL ANTICOAGULANTS 54
5.1.3 WARFARIN (VITAMIN K ANTAGONIST) 55
5.1.4 OTHER DRUGS 55
5.2 US ANTICOAGULATION THERAPY (PRODUCTS) MARKET FOR PT/INR TESTING DEVICES 56
5.2.1 INTRODUCTION 56
5.2.2 IN-OFFICE TESTING DEVICES 57
5.2.3 HOME TESTING DEVICES 58

6 US ANTICOAGULATION THERAPY MARKET FOR CLINICS 59
6.1 INTRODUCTION 60
6.2 US ANTICOAGULATION THERAPY MARKET FOR CLINICS, BY TYPE OF SERVICE 60
6.2.1 INTRODUCTION 60
6.2.2 TESTING SERVICES 62
6.2.3 CONSULTING SERVICES 62
6.3 US ANTICOAGULANT THERAPY MARKET FOR CLINICS, BY TYPE OF CLINIC 63
6.3.1 INTRODUCTION 63
6.3.2 HOSPITAL ASSOCIATED CLINICS 65
6.3.3 INDEPENDENT CLINICS 66
6.3.4 PHARMACY-BASED CLINICS 66
7 COMPANY PROFILES 67
(BUSINESS OVERVIEW, PRODUCTS OFFERED, STRENGTH OF PRODUCT PORTFOLIO, BUSINESS STRATEGY EXCELLENCE, RECENT DEVELOPMENTS.)*
7.1 INTRODUCTION 67
7.2 HOME TESTING DEVICES MANUFACTURERS 67
7.2.2 ABBOTT LABORATORIES 69
7.2.3 SIEMENS AG 71
7.2.4 COAGUSENSE, INC. 73
7.2.5 ALERE INC. 74
7.3 DRUG MANUFACTURERS 76
7.3.1 C. H. BOEHRINGER SOHN AG & CO. KG 76
7.3.2 BRISTOL-MYERS SQUIBB COMPANY 78
7.3.3 JOHNSON & JOHNSON 80
7.3.4 PFIZER, INC. 82
7.3.5 DAIICHI SANKYO COMPANY, LIMITED 84
7.3.6 PORTOLA PHARMACEUTICALS, INC. 86

LIST OF TABLES

TABLE 1 IMPACT ANALYSIS: MARKET DRIVERS 25
TABLE 2 COST DIFFERENCE: NOAC VS WARFARIN, PER PATIENT PER MONTH,
IN THE US (2015) 25
TABLE 3 IMPACT ANALYSIS: MARKET RESTRAINTS 26
TABLE 4 PIPELINE ASSESSMENT: ANTICOAGULANT REVERSAL AGENTS 27
TABLE 5 IMPACT ANALYSIS: MARKET OPPORTUNITIES 27
TABLE 6 IMPACT ANALYSIS: MARKET DRIVERS 30
TABLE 7 IMPACT ANALYSIS: MARKET RESTRAINTS 31
TABLE 8 IMPACT ANALYSIS: MARKET OPPORTUNITIES 32
TABLE 9 COMPONENT COST FOR DIFFERENT TREATMENT SETTINGS OF ANTICOAGULATION CLINICS 34
TABLE 10 LABORATORY PT/INR TESTING REIMBURSEMENT CODES & RATES 37
TABLE 11 PHYSICIAN-DIRECTED HOME PT/INR TESTING HCPCS REIMBURSEMENT CODES & RATES (NATIONAL) 39
TABLE 12 PHYSICIAN-DIRECTED HOME PT/INR TESTING HCPCS REIMBURSEMENT RATES (STATE-WISE) 39
TABLE 13 HOME PT/INR TESTING SERVICE REIMBURSEMENT AMBULATORY PAYMENT CLASSIFICATIONS (APCS) CODES & RATES UNDER HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM 42
TABLE 14 STATE REGULATORY BODIES FOR PT/INR TEST REIMBURSEMENT 42
TABLE 15 REIMBURSEMENT RATE FOR E&M SERVICES DURING ANTICOAGULATION
THERAPY (2015) 46
TABLE 16 PHYSICIAN-DIRECTED HOME PT/INR TESTING HCPCS REIMBURSEMENT CODES & RATES, 2009 VS. 2016 (NATIONAL RATE) 46
TABLE 17 LABORATORY PT/INR TESTING REIMBURSEMENT CODES & RATES,
2009 VS. 2016 (NATIONAL RATE) 47
TABLE 18 PRELIMINARY PAYMENT RATES IN 2018, 2019, AND 2020 (WITH 10% REDUCTION CAP WHEREVER APPLICABLE) 47
TABLE 19 COAGULATION ASSAY RESPONSIVENESS TO NOACS 48
TABLE 20 US ANTICOAGULATION THERAPY (PRODUCTS) MARKET FOR DRUGS, BY TYPE, 2015–2022 (USD MILLION) 54
TABLE 21 LIST OF NOVEL ORAL ANTICOAGULANTS AVAILABLE IN THE US MARKET 54
TABLE 22 AVERAGE COST OF ORAL ANTICOAGULANTS PER PATIENT PER MONTH IN THE US (2015) 55
TABLE 23 US ANTICOAGULATION THERAPY (PRODUCTS) MARKET FOR PT/INR TESTING DEVICES, BY TYPE, 2015–2022 (USD MILLION) 57
TABLE 24 US IN-OFFICE PT/INR TESTING DEVICES MARKET, 2015–2022 (USD MILLION) 57
TABLE 25 LEADING HOME TESTING DEVICES AVAILABLE IN THE US MARKET 58
TABLE 26 STATISTICS OF THROMBOEMBOLIC CONDITIONS IN THE US 60

TABLE 27 US ANTICOAGULATION THERAPY MARKET FOR CLINICS, BY TYPE OF SERVICE, 2015–2022 (USD MILLION) 61
TABLE 28 MAJOR ANTICOAGULATION CLINICS IN THE US 63
TABLE 29 US ANTICOAGULANT THERAPY MARKET FOR CLINICS, BY TYPE OF CLINIC,
2015–2022 (USD MILLION) 65


LIST OF FIGURES

FIGURE 1 US ANTICOAGULATION THERAPY MARKET SEGMENTATION 11
FIGURE 2 SECONDARY RESEARCH APPROACH 14
FIGURE 3 PRIMARY RESEARCH APPROACH 15
FIGURE 4 MARKET SIZING APPROACH 17
FIGURE 5 DATA TRIANGULATION METHODOLOGY 21
FIGURE 6 US ANTICOAGULATION DRUGS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 23
FIGURE 7 US ANTICOAGULATION THERAPY MARKET FOR CLINICS: DRIVERS, RESTRAINTS & OPPORTUNITIES 28
FIGURE 8 NUMBER OF PATIENT VISITS TO ANTICOAGULATION CLINICS, BY LINE OF THERAPY (2016 VS. 2022) 49
FIGURE 9 AVERAGE NUMBER/ PERCENTAGE SHARE OF NOAC THERAPY PATIENTS VISITING ANTICOAGULANT CLINICS, 2015 VS. 2020 50
FIGURE 10 EVOLUTION OF ANTICOAGULANTS 52
FIGURE 11 PERCENTAGE OF ANTICOAGULANTS PRESCRIBED FOR DIFFERENT INDICATIONS 53
FIGURE 12 NOACS, THE LARGEST SEGMENT IN THE US ANTICOAGULATION THERAPY (PRODUCTS) MARKET FOR DRUGS 53
FIGURE 13 IN-OFFICE TESTING DEVICES, THE LARGEST SEGMENT IN THE US ANTICOAGULATION THERAPY (PRODUCTS) MARKET FOR PT/INR TESTING DEVICES 56
FIGURE 14 TESTING SERVICES TO DOMINATE THE US ANTICOAGULATION THERAPY MARKET FOR CLINICS IN 2017 61
FIGURE 15 HOSPITAL-ASSOCIATED CLINICS SEGMENT WILL CONTINUE TO DOMINATE
THE US ANTICOAGULATION THERAPY MARKET FOR CLINICS IN 2022 63
FIGURE 16 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2016) 68
FIGURE 17 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2016) 69
FIGURE 18 SIEMENS AG: COMPANY SNAPSHOT (2016) 71
FIGURE 19 ALERE INC.: COMPANY SNAPSHOT (2016) 74
FIGURE 20 C. H. BOEHRINGER SOHN AG & CO. KG: COMPANY SNAPSHOT (2016) 76
FIGURE 21 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2016) 78
FIGURE 22 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2016) 80
FIGURE 23 PFIZER, INC.: COMPANY SNAPSHOT (2016) 82
FIGURE 24 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2015) 84
FIGURE 25 PORTOLA PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2016) 86


【レポートのキーワード】

抗凝固療法

★調査レポート[抗凝固療法の米国市場予測(~2022年)] ( US Anticoagulation Therapy Market by Product ((Anticoagulants Drugs (NOACs, Warfarin)), PT/INR Devices (In-Office, Home Testing)), Service Type (Testing & Consulting), Type of Clinic (Hospital Associated, Independent & Pharmacy-based) - Forecast to 2022 / MD-5704) 販売に関する免責事項
[抗凝固療法の米国市場予測(~2022年)] ( US Anticoagulation Therapy Market by Product ((Anticoagulants Drugs (NOACs, Warfarin)), PT/INR Devices (In-Office, Home Testing)), Service Type (Testing & Consulting), Type of Clinic (Hospital Associated, Independent & Pharmacy-based) - Forecast to 2022 / MD-5704) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆